Powell B L, Lyerly E S, Motsinger C P, Cruz J M, Chorley H M, Hurd D D, Cooper M R
Comprehensive Cancer Center, Wake Forest University, Winston-Salem, NC 27157-1082, USA.
Leukemia. 1995 May;9(5):770-3.
6-Thioguanine (6-TG) was administered as a continuous i.v. infusion for 7 days to 24 patients with relapsed or refractory acute leukemia or in the blast phase of chronic granulocytic leukemia. The daily dose of 6-TG was escalated from 37.5 mg/m2 to 160 mg/m2. Stomatitis was dose-related and dose-limiting with a maximum tolerated dose of 120 mg/m2 daily. Cutaneous reactions were dose-related but not dose-limiting. The recommended dose for phase II trials in acute leukemia is 120 mg/m2 per day as a continuous infusion for 7 days. There were two complete and four partial remissions among all patients. At the suggested phase II dose of 120 mg/m2 there were two complete remissions and one partial remission in five evaluable patients.
对24例复发或难治性急性白血病或慢性粒细胞白血病急变期患者，静脉持续输注6-硫鸟嘌呤（6-TG）7天。6-TG的日剂量从37.5mg/m²逐步增至160mg/m²。口腔炎与剂量相关且为剂量限制性毒性，最大耐受剂量为每日120mg/m²。皮肤反应与剂量相关但非剂量限制性毒性。急性白血病II期试验的推荐剂量为每日120mg/m²，持续输注7天。所有患者中有2例完全缓解和4例部分缓解。在建议的II期剂量120mg/m²时，5例可评估患者中有2例完全缓解和1例部分缓解。
